Pharmaceutical News and Articles

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA 30 January 2025 Alterity Therapeutics (ASX ATH, NASDAQ ATHE) ( Alterity or the Company ), a biotechnology company de

FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra

Monthly News Roundup - January 2025

FDA Clears Oral Journavx, a First-in-Class, Non-Opioid Pain Treatment from Vertex Pharmaceuticals On January 30th the FDA approved Journavx (suzetrigine) 50 mil

Bird Flu Is Spreading: What You Need To Know

A rapidly-spreading H5N1 avian influenza, otherwise known as bird flu, has been devastating bird flocks and showing signs of spreading to other mammals. Since 2

12 Questions To Ask Yourself and Your Doctor To Maintain Brain Health

If you ve experienced so-called senior moments, brain blips or brain freezes, you re not alone. Many people worry about their future brain health. So many, in f

Triple Semicircular Canal Plugging Effective for Vertigo Control in Meniere Disease

Triple semicircular canal plugging (TSCP) is effective for vertigo control but is associated with a risk for hearing loss in patients with Meniere disease (MD),

Propranolol May Reduce Overall Stroke Risk in Women With Migraine

Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke, accord

Bird Flu Studies Delayed as White House Halts CDC Reports

As a bird flu outbreak escalates across the U.S., the Trump administration has paused the release of key public health studies, stalling research that could pro

Intermittent Fasting Aids Some Outcomes for Postmenopausal Women With RA

Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis, according to a study published online J

FDA Approves Journavx, First New Non-Opioid Pain Pill in Decades

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin a